ISNES, Belgium, May 14, 2018 /PRNewswire/ -- VolitionRx Limited
(NYSE American: VNRX) ("Volition") today announced its
participation in the Bank of America Merrill Lynch 2018 Health Care
Conference being held from May 15-17,
2018 at the Encore Hotel in Las
Vegas, NV.
Scott Powell, Executive Vice
President of VolitionRx Limited and Chief Financial Officer of
Volition America, Inc., will provide an update on Volition's
business, clinical, regulatory and operational milestones.
Event:
|
Bank of America
Merrill Lynch 2018 Health Care Conference
|
Date:
|
Tuesday - Thursday,
May 15-17, 2018
|
Location:
|
Encore Hotel, Las
Vegas, NV
|
|
|
Persons attending the above-referenced conference who would like
to schedule a 1-on-1 meeting with Volition management during the
conference may do so by contacting Joseph
Green of Edison Advisors at JGreen@edisongroup.com or
Scott Powell, Executive Vice
President, at S.Powell@volitionrx.com.
About Volition
Volition is a multi-national life sciences company focused on
developing simple, easy to use, cost effective blood tests designed
to help diagnose a range of cancers. The tests are based on the
technology platform of Nucleosomics®, which is the practice of
identifying and measuring nucleosomes in the bloodstream or other
bodily fluid - an indication that disease is present.
As cancer screening programs become more widespread, Volition's
products aim to help to diagnose a range of cancers quickly,
simply, accurately and cost effectively. Early diagnosis has the
potential to not only prolong the life of patients, but also to
improve their quality of life. Volition's research and development
activities are currently centered in Belgium, with additional offices in
London, Texas and Singapore, as the company focuses on bringing
its diagnostic products to market first in Europe, then in the U.S. and ultimately,
worldwide.
For more information about Volition, visit Volition's website
https://volitionrx.com/
or connect with us via:
Twitter: https://twitter.com/volitionrx
LinkedIn: https://www.linkedin.com/company/volitionrx
Facebook: https://www.facebook.com/VolitionRx/
YouTube: https://www.youtube.com/user/VolitionRx
The contents found at Volition's website address, Twitter,
LinkedIn, Facebook, and YouTube are not incorporated by reference
into this document and should not be considered part of this
document. The addresses for Volition's website, Twitter, LinkedIn,
Facebook, and YouTube are included in this document as inactive
textual references only.
Media/Investor Contacts
Louise Day, Chief Marketing &
Communications Officer
l.day@volitionrx.com
+44 (0)7557 774620
Scott Powell, Executive Vice
President, Investor Relations
s.powell@volitionrx.com
+1 (646) 650 1351
Joseph Green, Edison Advisors
jgreen@edisongroup.com
+1 (646) 653 7030
Nucleosomics®, NuQ®, Nu.QTM and HyperGenomics® and
their respective logos are trademarks and/or service marks of
VolitionRx Limited and its subsidiaries. All other trademarks,
service marks and trade names referred to in this press release are
the property of their respective owners. Additionally, unless
otherwise specified, all references to "$" refer to the legal
currency of the United States of
America.
View original
content:http://www.prnewswire.com/news-releases/volitionrx-limited-to-attend-the-bank-of-america-merrill-lynch-2018-health-care-conference-from-may-15-17-2018-300647593.html
SOURCE VolitionRx Ltd